LOGIN  |  REGISTER
Astria Therapeutics
Chimerix

Elevance Health Announces Appearance at Bernstein’s 40th Annual Strategic Decisions Conference

May 20, 2024 | Last Trade: US$341.80 4.06 -1.17

INDIANAPOLIS / May 20, 2024 / Business Wire / Elevance Health (NYSE: ELV) announced today that senior management is scheduled to present at Bernstein's 40th Annual Strategic Decisions Conference in New York City, on May 31 at 9:00 a.m. Eastern Daylight Time (EDT). All interested parties are invited to listen to a live webcast of the presentation by visiting www.elevancehealth.com and selecting the “Investors” link. You may also access the link here.

For those unable to listen to the live webcast, a replay will be available for 90 days following the presentation.

To listen to the live webcast, please visit Elevance Health’s website www.elevancehealth.com at least 15 minutes early to download and install any necessary audio software. Individuals who listen to the presentations will be presumed to have read Elevance Health’s recent filings with the SEC, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023.

About Elevance Health, Inc.

Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 115 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.

C4 Therapeutics

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page